Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

VistaGen gains exclusive license to Pherin's PH94B anxiety compound, options PH10 for MDD

Executive Summary

VistaGen Therapeutics Inc. licensed exclusive worldwide development and commercialization rights to Pherin Pharmaceuticals Inc.'s PH94B (aloradine) nasal spray in Phase III for social anxiety disorder (SAD). In addition, VistaGen received an option to acquire an exclusive worldwide license to develop and sell PH10, Pherin's Phase II nasal spray candidate for major depressive disorder (MDD).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register